Insmed Announces First Quarter 2009 Financi...(from asset sale 127755 ...)

Date:5/13/2009

from asset sale 127,755 - Decreases in short-term investments - 5,601 Net cash provided by investing activities 127,755 5,601 Financing activities Repayment of convertible notes (553) (553) Certificate of deposits 10 - Other 25 - Net cash used in financing activities (518) (553) Increase in cash and cash equivalents 125,143 1,152 Cash and cash equivalents at beginning of period 2,397 3,554 Cash and cash equivalents at end of period $127,540 $4,706 Supplemental information Cash paid for interest $38 $68

'/>"/>

SOURCE Insmed Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference